Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications


Alamer A, Alrashed AA, Alfaifi M, et al. "Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis." Curr Med Res Opin. 2021;37(7):1085-1097. PMCID: PMC8146299  PMID: 33890544
Alamer AA, Almulhim AS, Alrashed AA, Abraham I. "Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic." Healthcare (Basel). 2021;9(2). PMCID: PMC7912160  PMID: 33525596
Mohzari YA, Alshuraim R, Asdaq SMohammed B, et al. "Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis." J Infect Public Health. 2021;15(1):1-6. PMID: 34852307
McBride A, Macdonald K, Fuentes-Alburo A, Abraham I. "Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer." J Med Econ. 2021;24(1):743-756. PMID: 34003067
Alkhatib N, Sun D, Denhaerynck K, et al. "Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients." Curr Med Res Opin. 2021;37(1):1-8. PMID: 33206572
Fazel M, AlRawashdh N, Alamer A, Curiel-Lewandrowski C, Abraham I. "Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma." Expert Opin Biol Ther. 2021;21(12):1647-1653. PMID: 34693839
Alrashed AA, Khan TM, Alhusseini NK, et al. "Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study." J Infect Public Health. 2021;14(6):726-733. PMCID: PMC7986317  PMID: 34020213


Oh M, Patanwala AE, Alkhatib N, Almutairi A, Abraham I, Erstad B. "Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective." Crit Care Med. 2020;48(10):e906-e911. PMID: 32701552
Macdonald K, McBride A, AlRawashdh N, Abraham I. "Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv." J Med Econ. 2020;23(12):1466-1476. PMID: 33023360
McBride A, Wang W, Campbell K, Balu S, Macdonald K, Abraham I. "Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim." J Med Econ. 2020;23(8):856-863. PMID: 32323582